BIOLASE, Inc. , a medical device company, develops, manufactures, markets, and sells laser systems in dentistry and medicine for patients and health care professionals in the United States and internationally. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; and diode laser systems, which are used to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of dental procedures, such as cosmetic, restorative, and complex surgical applications. The company also markets, sells, and distributes dental imaging equipment, including three-dimensional (3D) CAD/CAM intra-oral scanners and digital dentistry software. Its dental imaging products comprise 3Shape Trios intraoral scanners, digital impression systems, and software for taking 3D scans, which are used to design crowns, study models, surgical guides for implant placement, and event orthodontic and athletic appliances. In addition, the company manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces. It sells its products primarily to dentists in general practice through its field sales force and distributor network. BIOLASE, Inc. was founded in 1984 and is headquartered in Irvine, California.

  • BIOLASE Hosts Nearly 400 Dental Professionals During Webinar On Landmark Study On Lasers And Managing Periodontitis
    on September 15, 2020 at 12:30 pm

    BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it hosted nearly 400 dental professionals last Thursday evening during a panel discussion on the NEW Journal of Periodontology landmark study from the McGuire Institute comparing periodontal flap surgery to BIOLASE's REPAIR Perio laser protocol in managing periodontitis.

  • BIOLASE To Present At H.C. Wainwright's 22nd Annual Global Investor Conference
    on September 11, 2020 at 8:05 pm

    BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that Todd Norbe, President and Chief Executive Officer and John Beaver, Chief Operating Officer and Chief Financial Officer, will be providing an overview of the Company, as well as recent progress and achievements at the H.C. Wainwright 22nd Annual Global Investor Conference on Wednesday, September 16, 2020 at 11:00 am Pacific Time (2:00 pm ET).

  • BIOLASE to Highlight Progress and Recent Achievements at the Colliers & Co. Institutional Investor Conference
    on September 3, 2020 at 12:30 pm

    BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that Todd Norbe, President and Chief Executive Officer and John Beaver, Chief Operating Officer and Chief Financial Officer, will be providing an overview of the Company, as well as recent progress and achievements at the Colliers & Co. Institutional Investor Conference on Thursday, September 10, 2020. The conference will feature virtual one-on-one meetings with the BIOLASE' executives and institutional investors are invited to request meeting times at tkehrli@evcgroup.com or through their Colliers representative.

  • BIOLASE to Present at the LD Micro 500 Virtual Conference
    on August 24, 2020 at 10:30 am

    FOOTHILL RANCH, CA / ACCESSWIRE / August 24, 2020 / BIOLASE, Inc.

  • BIOLASE Regains Nasdaq Compliance For Minimum Stockholder Equity
    on August 18, 2020 at 10:30 am

    BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that it received notification from the Listing Qualifications Department of the Nasdaq Stock Market indicating that the Company now meets the minimum stockholders equity requirement of $2.5 million set forth in Listing Rule 5550(b)(1). Following the registered direct offering in June and the recently completed $18.0 million Rights Offering in July, Nasdaq has determined that the Company is now in compliance with the minimum stockholders equity requirement.

  • BIOLASE Reports Second Quarter 2020 Financial Results
    on August 13, 2020 at 8:05 pm

    BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced its financial results for the second quarter ended June 30, 2020 and provided a business update.

  • BIOLASE, Inc. to Report Second Quarter 2020 Results on August 13, 2020
    on August 11, 2020 at 8:43 pm

    BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it will release second quarter 2020 financial and operating results on Thursday, August 13, 2020 after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and corporate developments.

  • BIOLASE Announces Closing Of Oversubscribed Rights Offering
    on July 22, 2020 at 8:05 pm

    BIOLASE, Inc. (NASDAQ: BIOL), a global leader in dental lasers, further strengthened its balance sheet today as it closed the Company's previously announced rights offering (the "Offering"). At the closing, BIOLASE issued and sold an aggregate of 18,000 shares of its Series F convertible preferred stock, each of which is convertible into 2,500 shares of our common stock at a conversion price of $0.40 per share and warrants to purchase an additional 45,000,000 shares of our common stock at an exercise price of $0.40 per share, pursuant to the exercise of subscription rights and oversubscription rights in the Offering. The Offering, which was oversubscribed, raised total gross proceeds of $18.0 million, excluding any proceeds that may be received by the Company from the future exercise of the warrants included in the units. BIOLASE believes that the proceeds it received in the Offering, when combined with the $5.0 million it had in cash and cash equivalents on June 30, 2020 will enable the Company to effectively execute on its growth strategy.

  • BIOLASE Announces Expiration Of Oversubscribed Rights Offering
    on July 16, 2020 at 10:30 am

    BIOLASE, Inc. (NASDAQ: BIOL), a global leader in dental lasers, announced today the expiration of the Company's rights offering, which was oversubscribed. The subscription period for its previously announced rights offering (the "Offering") of units at a subscription price of $1,000 per unit, consisting of one share of the Company's newly created Series F Convertible Preferred Stock with a face value of $1,000 (and immediately convertible at the option of the holder into shares of BIOLASE's common stock at a conversion price of $0.40 per share) and 2,500 warrants to purchase BIOLASE's common stock with an exercise price of $0.40 per share, expired on July 15, 2020, and these rights are no longer exercisable.

  • Landmark Head-to-Head Study Published in Journal of Periodontology Concludes That BIOLASE REPAIR® Perio Protocol is Superior for Procedure Time and Patient-Reported Outcomes
    on July 13, 2020 at 12:00 pm

    BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced data published in the Journal of Periodontology from a clinical trial conducted at The McGuire Institute™. Designed to meet the stringent American Association of Periodontology Best Evidence Consensus (BEC) standards, this first-of-its-kind study compared BIOLASE's REPAIR® Perio protocol to the traditional Minimally Invasive Surgical Technique (MIST) treatment of moderate to severe generalized periodontitis.

[custom-facebook-feed id=Biolase ownaccesstoken=true pagetype=page seemoretext=’Expand’ ajax=true]

Hey hygienists! 👋 Don't forget to sign up for an All-New #HygieneWebinar tomorrow! This panel of #Hygienists will be discussing today's new norm around #dentalsafety and #hygiene patients. Check out all the details below! 🤩🦷

https://bit.ly/2ZpgVl8

Better Perio is Here! Join Dr. Preety Desai for this all-new educational #webinar on laser-assisted #periodontics. Learn more about our versatile minimally invasive #Waterlase technology and the advantages for dental practitioners as well as patients.

https://bit.ly/3bR59Fm

Did you know #BIOLASE offers FREE #VirtualStudyClubs (VST)? If you haven’t already been part of a BIOLASE VSC, this is your chance to join Dr. Howard Golan for this free VSC session. Check out all the details in the link below!

https://bit.ly/2RouAV0

Better Perio is Here! Join Dr. Preety Desai for this all-new educational #webinar on laser-assisted #periodontics. Learn more about our versatile minimally invasive #Waterlase technology and the advantages for dental practitioners as well as patients.

https://bit.ly/3bR59Fm

Hey #hygienists!👋 You asked for it and it's here! All-New Hygiene #Webinar panel discussing today's new norm around #dentalsafety and hygiene patients. Check out all the details below! 🤩🦷

https://bit.ly/2ZpgVl8

COMING LIVE TOMORROW! You’ve heard the news! Now witness the ALL-NEW LANDMARK CLINICAL STUDY IN #PERIODONTITIS Conducted by The #McGuireInstitute™ and published in The Journal of Periodontology. @AmerAcadPerio

REGISTER NOW! https://bit.ly/3gLLU0o

"#Dentallasers have enhanced the productivity, comfort and speed at my practice. First, we have been able to increase the number of procedures we can do in-house without having to refer patients out." - Dr. Patrick Ruehle

https://bit.ly/3i1e2yj

You’ve heard the news! Now witness the ALL-NEW LANDMARK CLINICAL STUDY IN PERIODONTITIS Conducted by The McGuire Institute™ and published in The Journal of Periodontology!

Load More...

FULL NAME*

What's Your Role?*

WORK EMAIL*

COMPANY NAME*

Company Description*

HOW'D YOU HEAR ABOUT US?

DETAILS ABOUT YOUR GOALS

BIOLASE, Inc.

4 Cromwell
Irvine, CA 92618

+1 (949) 361-1200

www.biolase.com

September 2020
S M T W T F S
 12345
6789101112
13141516171819
20212223242526
27282930  

©2020 ALIGNMT LLC | Alignment Strategy | Mergers & Acquisitions | Investor Relations

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

Log in with your credentials

or    

Forgot your details?

Create Account